BioSpace News Archive

QMC HealthID, a wholly owned subsidiary of Quantum Materials Corp, today announced that it has partnered with Tried & Tested COVID-19 testing services.

Benchtop Lab Equipment Reports Record Revenues and Earnings Company Continues to Invest In Its Bioprocessing Business

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the promotion of Eric Feldman, M.D., to Senior Vice President and Chief Medical Officer.

Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced that it has begun selling its CompuFlo® Epidural Instrument and related disposables to the University Hospital of Würzburg , one of the leading national hospitals in Germany. Dr. Peter Kranke, Professor of Anesthesia in the Department of Anesthesia

In an ongoing effort to expand access to COVID-19 vaccines and help the country move forward from the pandemic, CVS Health announced that it will begin to administer vaccines to eligible populations at 81 select CVS Pharmacy, CVS Pharmacy y más, and Navarro Discount Pharmacy locations across Florida.

MiRus announced that they will offer a LIFETIME LIMITED WARRANTY on its Molybdenum-Rhenium superalloy rod technology.

B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, today announced that James Allen has joined the company’s Executive Leadership Team and will assume the role of Senior Vice President and Chief Financial Officer following a transition period

Rapid Micro Biosystems, the leading provider of automated, non-destructive, rapid microbial detection, is pleased to announce the appointment of Gurinder Grewal as Senior Vice President of Strategy, reporting directly to the company’s CEO, Robert Spignesi.

Quantum Leap Healthcare Cooperative (Quantum Leap) and SignalPath announced a partnership today that will further empower the I-SPY platform trials with robust, streamlined technology infrastructure to drive the ease and efficiency of trial execution.

Teon Therapeutics, a biopharmaceutical company developing small molecules that inhibit the immunosuppressive and cancer-promoting signaling pathways, today announced the completion of a $30M Series A financing.